Clinical Trials Logo

Filter by:
NCT ID: NCT06322043 Not yet recruiting - Volume Deficiency Clinical Trials

Evaluation of Safety of Filler Injection in Subcutaneous Tissues

Start date: April 2024
Phase: N/A
Study type: Interventional

Adipearl is an injectable filler intended to be injected subcutaneously.

NCT ID: NCT06317870 Not yet recruiting - Analgesia Clinical Trials

Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty

PENGIT
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to compare the analgesic effect of pericapsular nerve block (PENG) with intrathecal morphine in patients scheduled for total hip replacement surgery. The main question to be answered is whether the PENG block is equivalent to intrathecal morphine in reducing postoperative pain. Participants will be randomised into two groups. Patients assigned to the PENG group will receive spinal anaesthesia with local anaesthetic (isobaric bupivacaine) alone and a PENG block. Patients assigned to the intrathecal morphine (ITM) group will receive spinal anaesthesia with a mixture of local anaesthetic (isobaric bupivacaine) and morphine (100 mcg) and a sham PENG block to ensure patient blinding.

NCT ID: NCT06305182 Not yet recruiting - Anorexia Nervosa Clinical Trials

Metreleptin in Anorexia Nervosa

METRAN
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The treatment of anorexia nervosa often proves to be difficult. There are no drugs that work specifically for the treatment of anorexia nervosa. Experimental administration of metreleptin (synthetically produced leptin) to patients with anorexia nervosa has produced positive results. This study tests the effect of metreleptin in comparison with placebo, which could potentially make treatment easier. The aim of the study is to investigate whether treatment with metreleptin can help to reduce the symptoms of anorexia nervosa and improve mood and weight.

NCT ID: NCT06293677 Not yet recruiting - Febrile Neutropenia Clinical Trials

Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance

DAR-ARC
Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

This clinical trial focuses on children with cancer who face infections after receiving chemotherapy. Chemotherapy affects the bone marrow, leading to a decrease in the production of certain white blood cells, particularly those that defend against bacterial infections (neutrophils). One significant concern is febrile neutropenia, where children experience a fever during a period of low white blood cell count. This condition often results from bacterial infections, necessitating prompt wide-spectrum antibiotic treatment. However, some children eliminate antibiotics in the urine too quickly during febrile neutropenia. Their kidneys function more than they normally do (renal hyperfiltration). This can lead to insufficient exposure to antibiotics to control the infection. The current standard antibiotic regimens do not account for this variable elimination rate. In this study we focus on two antibiotics used in this context: piperacillin-tazobactam and meropenem. The main questions this study aims to answer are, in these children: - Would higher doses of antibiotics result in better blood levels of antibiotics? - Would they have more sides effects with higher antibiotics dosages? - Would they recover more quickly with higher antibiotic doses? All patients will undergo a blood test upon hospital arrival, including an assessment of renal function. If renal function is normal or diminished, the patient will receive the standard antibiotic dose. Children with increased renal function will be randomly assigned to two groups during each episode of febrile neutropenia. One group will receive standard antibiotic dosages, while the other will receive higher doses to compensate for renal hyperfiltration. Throughout the study, antibiotic levels in the blood will be monitored for all patients. This monitoring will determine if target concentrations can be achieved more quickly with experimental dosages and will allow doctors to readjust the doses if needed.

NCT ID: NCT06292988 Not yet recruiting - Clinical trials for Medullary Thyroid Cancer

Predictive Factors for Medullary Thyroid Cancer Aggressiveness

MYELO
Start date: March 1, 2024
Phase:
Study type: Observational

This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival.

NCT ID: NCT06281106 Not yet recruiting - Psoriasis Clinical Trials

TYK2 Inhibition in Paradoxical Psoriasis

TYPP
Start date: April 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists. This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.

NCT ID: NCT06274879 Not yet recruiting - Bile Duct Cancer Clinical Trials

Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer

Ablatio
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of chemotherapy (gemcitabine and cisplatin) plus durvalumab (immune-checkpoint-inhibitor, ICI). The main question it aims to answer is whether it is safe to combine chemotherapy (gemcitabine and cisplatin) and immunotherapy (durvalumab) - CICI therapy. Participants will be assigned to either the control group or the experimental group. In the control group, the standard of care consists of endoscopy with stent placement in the bile duct and CICI, whereas in the experimental group, bRFA will be performed in addition to the standard of care. Participants will be followed up for 6 months, during the follow-up, the stage of the tumor, blood examination, the duration of the stent from the insertion until its failure, adverse events and quality of life will be examined. Researchers will compare the standard of care alone to the experimental group to see if the additional bRFA procedure causes higher or no difference in adverse events rate.

NCT ID: NCT06269315 Not yet recruiting - Clinical trials for Hand Disinfectant Exposure

Assessment of Skin Barrier Disruption Due to Daily Use of Cleaning Products and Hand Disinfectants

SBDDCP
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to assess the effects of household detergents and hand disinfectants on human skin barrier integrity among healthy adult volunteers. The main questions it aims to answer are: - How does exposure to household detergents and hand disinfectants impact skin barrier function? - Are there differences in skin barrier disruption between various types of cleaning agents and disinfectants? Participants will: Undergo patch testing with controlled amounts of household detergents and hand disinfectants on a small area of their skin. Be monitored for adverse reactions during and after exposure. Have their skin barrier integrity assessed using electrical impedance spectroscopy at multiple time points post-exposure. If there is a comparison group: Researchers will compare the effects of different types of cleaning agents, hand disinfectants, and their ingredients on skin barrier integrity to determine variations in their impact.

NCT ID: NCT06258291 Not yet recruiting - Septic Shock Clinical Trials

First in Human Trial to Assess the Safety of HemoSystem REBOOT in Patients With Sepsis-induced Immunosuppression

RESTORE I
Start date: October 15, 2024
Phase: N/A
Study type: Interventional

The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.

NCT ID: NCT06250582 Not yet recruiting - Virtual Reality Clinical Trials

Does Virtual Reality Improve Symptom Burden in Dialysis Patients?

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the use of virtual reality therapy in dialysis patients. The main question it aims to answer is: Does virtual reality improve symptom burden in dialysis patients and improve their mental wellbeing? Over a period of one month, one virtual reality therapy session of 30 minutes will be performed during each regular hemodialysis session. Since we will conduct a monocentric, crossover randomized controlled trial, the participants act as their own control group.